Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Outlines Plans To Establish Lantus As Leading Worldwide Anti-Diabetic

Executive Summary

Sanofi-Aventis aims to establish its long-acting insulin Lantus (insulin glargine injection) as the leading anti-diabetic worldwide by marketing it for combination use as well as a stand-alone product

You may also be interested in...



Diabetes Trials: FDA Wants Bigger Studies; Industry Suggests Counting Phase II

Industry is striking a generally positive tone in comments on FDA's draft guidance on diabetes product development, but is expressing concern about the recommendation that the size of trials should be increased

Diabetes Trials: FDA Wants Bigger Studies; Industry Suggests Counting Phase II

Industry is striking a generally positive tone in comments on FDA's draft guidance on diabetes product development, but is expressing concern about the recommendation that the size of trials should be increased

Sanofi’s Lovenox Weathers Heparin Storm; Pipeline Faces Some Setbacks

Sanofi-Aventis' antithromboticLovenox is currently enjoying a bump from the fallout of the heparin scandal, with increased sales in the U.S. where the low molecular weight heparin is produced domestically. But it may be short-lived, as Momenta and Sandoz are gearing up to re-submit their ANDA for enoxaparin

Related Content

UsernamePublicRestriction

Register

PS049320

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel